- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
Carey Anders, MD
Associate Professor, Medical Oncology
University of North Carolina
Chapel Hill, North Carolina
Conquer Cancer Foundation of ASCO
Studying the relationship between tumor microenvironment and breast cancer brain metastasis
Creating dataset of predictive markers for the prevention of brain metastasis
May uncover novel approaches to prevent or treat breast cancer brain metastasis, a particularly devastating disease
Breast cancer brain metastases are a serious clinical problem associated with poor prognosis with no approved systemic therapy. Identifying the underlying biology driving breast cancer brain metastases is critical to the development of effective anti-cancer agents to prevent and treat this disease.
Dr. Anders' Conquer Cancer Foundation research supported by BCRF is focused on the tumor genetics and the tumor microenvironment in brain metastases. In particular, she is interested in the brain microenvironment and tumor-infiltrating immune cells.
She is constructing a dataset that can be used to create prognostic and/or predictive models for brain metastases. This will also be helpful in identifying novel therapeutic targets that can be tested in rationally-designed clinical trials for future treatment or prevention of brain metastases.
Carey K. Anders, MD is an Associate Professor of Medicine at the University of North Carolina (UNC) School of Medicine and an active member of the UNC Lineberger Comprehensive Cancer Center. As a clinician-scientist, she is Section Leader for the UNC Breast Program, Leader of the UNC breast cancer clinical trials program, and co-Director of the multi-disciplinary brain metastases clinic at UNC. Dr. Anders’ translational research program, which spans bench to bedside, focuses on the biology of triple negative breast cancer and brain metastases. She serves as the principal investigator for multiple clinical trials evaluating novel anti-cancer agents to more effectively treat patients with advanced triple negative breast cancer and brain metastases. In parallel and supported by the UNC Chapel Hill Hematology Oncology K12, NIH/NCI K23, LCCC SPORE and Damon Runyon Clinical Investigator Award, she has developed multiple intracranial breast cancer tumor models to test novel therapies, including small molecule and nanoparticle chemotherapeutics in the laboratory. She is also devoted to uncovering the genetic and genomic underpinnings of triple negative breast cancer and brain metastases using Next Generation Sequencing, which is the focus of her Conquer Cancer Foundation Advanced Clinical Research Award supported by BCRF. Her ultimate goal is to translate preclinical findings into rationally-designed therapeutic strategies to improve survival and enhance quality of life for the many patients facing a diagnosis of triple negative breast cancer brain metastases.